Recursion Pharmaceuticals Stock News

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 1.49%) is slimming down and streamlining. After the biotech updated its strategy to do so on Tuesday, investors became more hopeful on its future, bidding the stock up; it closed 1.6% higher at the end of the day.

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech industry downturn.

Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company Recursion (NASDAQ: RXRX), today announced the open-source release of Boltz-2, a first of its kind biomolecular foundation model. Powered by Recursion's NVIDIA supercomputer for i...

Salt Lake City, May 30, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:

Most investors are best served by owning high-quality "forever" stocks, even if these stocks are only apt to produce average returns.

Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention.

The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automation, operational efficiency, and dramatic improvements in workforce productivity.

Shares of Recursion Pharmaceuticals (RXRX -1.48%) fell this week. The stock lost 24% as of market close on Friday.